UB-311 is a novel immunotherapeutic for the treatment of Alzheimer’s Disease (AD). The UBI vaccine employs the UBITh helper T cell technology and a particular site-specific epitope to target the amyloid-beta peptide.
UB-311 has successfully completed clinical Phase I study, demonstrating safety and tolerability. UBI is initiating a Phase II study.
Currently there are no effective treatments for AD on the market. An efficient AD drug would serve an unmet need and demand is virtually inestimable. For a rough estimate of market size consider that one in 10 persons over 65 and nearly half of those over 85 have AD and that in the US alone, at least US$100 billion a year is spent on AD.